Pharmaceutical

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company…

4 months ago

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest…

4 months ago

Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)

Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with…

4 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA…

4 months ago

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting

Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy developmentHOLLISTON, Mass.,…

4 months ago

Vanqua Bio to Participate in Upcoming Scientific Conferences

CHICAGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for…

4 months ago

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

Company to present new data, highlighting progress in its therapeutics program for recurrent glioblastoma (rGBM)AUSTIN, Texas, Sept. 18, 2024 (GLOBE…

4 months ago

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of…

4 months ago

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September…

4 months ago